To assess the involvement of vascular endothelial cell activation and damage in stem cell transplantation (SCT)-related complications, such as acute and chronic GVHD and thrombotic microangiopathy (TMA), we investigated the changes in serum levels of soluble forms of vascular cell adhesion molecule-1 (sVCAM-1) and Eselectin (sE-selectin) in SCT. The soluble form of intercellular adhesion molecule-1 (sICAM-1) was also analyzed. In patients with acute GVHD (grades II-IV), serum levels of sE-selectin and sICAM-1 increased around onset of GVHD (day 30). While the increase of sE-selectin levels was transient, sICAM-1 levels remained high until day 60. In patients with extensive chronic GVHD, sVCAM-1 as well as sE-selectin levels significantly increased. The appearance of clinical symptoms was preceded by elevations of sVCAM-1 and sE-selectin levels on day 60, and sICAM-1 levels on days 30 and 60. For the analysis of TMA, to exclude the influence of GVHD, serum levels were measured in auto-SCT patients. Around the onset of TMA, sVCAM-1 and sE-selectin levels significantly increased in patients with TMA without an increase of sICAM-1 levels. These findings support the notion that activation and injury of endothelium are commonly involved in the pathogenesis of acute and chronic GVHD and TMA. Bone Marrow Transplantation (2001) 27, 977-982.
GVHD. TMA, a characteristic form of endothelial cell damage, has been associated with acute GVHD, cytotoxic drugs, irradiation, and viral infections such as cytomegalovirus and human herpesvirus-6 in patients with BMT. [1] [2] [3] [4] [5] It is well known that damage or activation of vascular endothelial cells, mediated by cytokines such as interleukin-1 or tumor necrosis factor-␣, induces expression of vascular adhesion molecules, ie intercellular adhesion molecule-1 (ICAM-1), vascular adhesion molecule-1 (VCAM-1), and E-selectin, on their cell surface. 6 This process appears to be important in the recruitment of leukocytes to the site of inflammation. [7] [8] [9] [10] When endothelium is activated in this way, soluble forms of ICAM-1, VCAM-1 and Eselectin are shed into plasma by the proteolytic cleavage of their membrane-bound counterparts from activated leukocytes and endothelial cells, and/or by the differential splicing of their transcripts. 6, 11 Among these adhesion molecules, ICAM-1 is distributed to a broad range of tissues, including vascular endothelial cells and leukocytes, and it is thought to be indicative of the overall level of inflammation. 12 On the other hand, expression of VCAM-1 is more restricted to endothelium and E-selectin is only documented on endothelial cells. 12, 13 Therefore, these soluble adhesion molecules are considered to be markers of endothelial cell damage and activation. In order to assess the involvement of endothelial cell damage during the course of acute and chronic GVHD, and TMA, we investigated the changes in serum levels of soluble forms of VCAM-1 (sVCAM-1) and E-selectin (sE-selectin) in SCT. The soluble form of ICAM-1 (sICAM-1) was also analyzed for the assessment of inflammatory status as well as endothelial cell damage.
Patients and methods

Patients
We studied 49 selected patients (aged 1-18 years) who received SCT from 1993 to 2000, excluding those complicated with severe infection, such as pneumonia and sepsis and those who were not in complete remission at the time of SCT. Thirty-one patients received allo-SCT (21 from related, 10 from unrelated donors). Diagnoses included ALL (n = 15), AML (n = 14) and juvenile myelomonocytic leukemia (n = 2). Twenty-six and five patients underwent conditioning regimens with and without TBI, respectively. Prophylaxis for GVHD was principally a combination of cyclosporin A or tacrolimus, and short-term methotrexate. Prednisolone was administered for the treatment of GVHD. Acute GVHD was graded clinically according to the criteria of Prezepiorka et al 14 and patients were classified into two groups: no or grade I acute GVHD (16 patients) and grades II-IV acute GVHD (15 patients). The severity of chronic GVHD was classified into two groups according to the criteria of Shulman et al: 15 no or limited chronic GVHD (19 patients) and extensive chronic GVHD (nine patients). Of nine patients with extensive chronic GVHD, it developed de novo in three patients and progressed from acute GVHD in the other six patients. Eighteen patients received auto-SCT: of these, 16 and two patients had solid tumors and hematological malignancies, respectively. All patients received conditioning regimens consisting of alkylating agents without TBI. Of the 18 patients who received auto-SCT, seven were affected by TMA. The diagnosis of TMA was based on clinical features characterized by neurologic disturbance, microangiopathic hemolytic anemia, renal insufficiency, and thrombocytopenia. The onset of TMA was 2-3 weeks after SCT and clinical findings gradually improved at 40-50 days after SCT in all patients. No specific treatment was given except for two patients who received plasma exchange. These two patients were reported previously. 5 
Measurements
After obtaining informed consent, heparinized venous blood samples were collected from patients on days 0, 30, 60, 100 and 180. Plasma was obtained after centrifugation at 3000 g for 5 min at 4°C and stored at −20°C until assayed.
sICAM-1 and sE-selectin levels were measured with enzyme-linked immunosorbent assay (ELISA) kits from Bender MedSystems (Vienna, Austria), and sVCAM-1 was measured using an ELISA kit from R & D Systems (Minneapolis, MN, USA). ELISA kits were used according to the manufacturer's instructions. All measurements were performed in duplicate.
All results are shown as mean ± s.d. Statistical analysis used the Student's t-test; P values Ͻ0.05 were considered significant.
Results
Comparison of auto-and allo-SCT
Serum levels of sVCAM-1, sE-selectin and sICAM-1 increased significantly on day 30 after allo-and auto-transplantation as compared with day 0 (P Ͻ 0.05). While sVCAM-1 and sE-selectin levels remained elevated on days 60 and 100, the concentration of sICAM-1 slightly decreased on day 60 post transplantation. Although the level of sICAM-1 was higher in the allo-SCT than in the auto-SCT group, the difference was not statistically significant. There were no differences in serum levels of sVCAM-1 and sE-selectin between the auto-and allo-SCT groups at any time point (Figure 1 ).
Comparison of patients with and without GVHD after allo-SCT
In allo-SCT, the serum level of sE-selectin increased significantly (P Ͻ 0.05) in patients with acute GVHD (grades II-IV) at the time of acute GVHD onset (day 30), but the increase was transient (Figure 2 ). sICAM-1 levels in patients with acute GVHD were significantly (P Ͻ 0.05) higher than in patients with no or grade I GVHD on day 30 and remained higher at day 60. There was no statistically significant difference in sVCAM-1 levels between these groups of patients at day 30 or 60.
As shown in Figure 3 , around the onset of chronic GVHD (day 100), both sVCAM-1 and sE-selectin levels were significantly (P Ͻ 0.05) higher in patients with extensive chronic GVHD than in patients without GVHD. The increase in both these soluble adhesion molecules in the group that developed extensive chronic GVHD was also significant (P Ͻ 0.05) before clinical presentation of GVHD (day 60). The levels of sVCAM-1 and sE-selectin in the patients with extensive chronic GVHD decreased to those of the patients without GVHD on day 180. The serum level of sICAM-1 was significantly (P Ͻ 0.05) higher on days 30 and 60 in the patients who subsequently developed extensive chronic GVHD than in the patients who did not develop GVHD. Thus, the subsequent onset of extensive cGVHD seems to be predictable on day 30 or 60 in some patients. Individual values of each patient are shown in Figure 4 .
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Comparison of patients with and without TMA after auto-SCT
To analyze the effect of TMA on adhesion molecules without the influence of GVHD, serum levels of soluble adhesion molecules were measured in patients with auto-SCT. Seven patients who were diagnosed for SCT-associated TMA around days 15-20 after SCT were compared to eight patients without TMA. In the patients with TMA, sVCAM-1 levels increased significantly (P Ͻ 0.05) at 30 days after SCT and reached a peak at day 60 ( Figure 5) . Thereafter, the serum concentration of sVCAM-1 decreased to that of the patients without TMA at day 100. However, the level of sE-selectin increased transiently with the development of TMA, but there was no statistically significant difference between patients with and without TMA, probably because of the relatively small numbers of analyzed patients. There was no statistically significant difference in sICAM-1 between the groups with and without TMA at any time point.
Discussion
Serum levels of soluble adhesion molecules are significantly influenced by infection such as pneumonia, neutrophil counts and the presence of leukemia cells. 16, 17 Therefore, in this study those were compared among patients who received SCT after achievement of complete remission and patients complicated with severe infection were excluded. In all patients who underwent allo-and auto-SCT, serum levels of sVCAM-1, sE-selectin and sICAM-1 increased significantly after transplantation. This observation suggests that conditioning regimens consisting of high-dose chemotherapy with or without radiotherapy injured endothelial cells. Such damage seemed to be enhanced by inflammatory cytokines produced during conditioning and hematopoietic reconstitution, which induced expression of vascular adhesion molecules. 18, 19 Antineoplastic agents and irradiation are toxic towards endothelial cells, [20] [21] [22] but levels of the three adhesion molecules following conventional chemotherapy were not significantly changed (data not shown). Although there was no significant difference in the serum level of these soluble adhesion molecules after alloand after auto-SCT, sICAM-1 level tended to be slightly higher after allo-SCT, which probably reflects activation of lymphocytes caused by an allo-response.
In patients with severe acute GVHD (у grade II), a significant increase in sE-selectin levels has been observed around the onset of GVHD (day 30), suggesting the association of acute GVHD with endothelial activation and injury. Indeed, expression of E-selectin had been observed on epithelial cells histologically in patients with documented acute GVHD. [23] [24] [25] Unlike other histological reports, sICAM-1 levels in severe acute GVHD patients were significantly higher on days 30 and 60. sICAM-1 is thought to be shed as a result of activation of endothelial cells and immunocytes. 6, 26 A significant increase in sE-selectin was observed in patients with extensive chronic GVHD. In addition, in contrast to the finding in acute GVHD, sVCAM-1 levels also increased and the increases of both soluble adhesion molecule levels were preceded by a transient elevation of sICAM-1 levels. While VCAM-1 is more restricted to endothelium and E-selectin is only described on endothelial cells, 12, 13 ICAM-1 is distributed to activated lymphocytes and neutrophils as well as endothelial cells. 12 Therefore, this finding suggests that inflammatory responses involving production of inflammatory cytokines, reflected in the elevation of sICAM-1 levels, trigger generalized vasculitis, leading to the increase of sVCAM-1 and sE-selectin concentrations. Surface expression of VCAM-1 and E-selectin on vascular endothelial cells has been shown to increase in response to proinflammatory cytokines such as IL-1 and TNF-␣ which are abundantly produced during chronic GVHD. 27, 28 The difference in sVCAM-1 levels between acute and chronic GVHD may indicate that vasculitis plays a more important role in the pathogenesis of chronic GVHD. sVCAM-1 interacts with NK cells constitutively and with activated CD45RO + T cells via ␣4 integrins. 29 In addition, sVCAM-1 exhibits chemotactic activity for memory T cells and monocytes. 30, 31 Therefore, sVCAM-1 itself, when abundant in serum, might participate in the pathogenesis of chronic GVHD. However, negative regulation of sVCAM-1 on T cell proliferation has also been reported 32 and sVCAM-1 may act as a competitive ligand inhibitor leading to downregulation of the inflammatory response by altering leukocyte trafficking. sE-selectin directs movement of polymorphonuclear leukocytes and sICAM-1 mediates both activation of T cells and inhibition of cell adhesion to endothelial cells. [33] [34] [35] Thus, roles of these soluble adhesion molecules are complicated. Further study is needed to reveal their exact role in the development of chronic GVHD. Interestingly, there was a significant increase in sVCAM-1 and sE-selectin levels on day 60 and in sICAM-1 levels on days 30 and 60 before exhibition of clinical symptoms of chronic GVHD. Thus, high concentrations of these soluble adhesion molecules may predict the occurrence of chronic GVHD in some patients. Like the present study, a previous report has demonstrated an increase of sICAM-1 levels on days 30 and 60 in patients with chronic GVHD and it was suggested that secretion of sICAM-1 arose from damaged bile ducts. 36 In order to analyze the pathogenesis of TMA excluding the influence of an allo-response, soluble adhesion molecule levels were measured in patients with auto-SCT. A significant elevation of sVCAM-1 level was observed in patients with TMA on day 30 when TMA developed, indicating that endothelial cell activation and injury occurs in TMA. The serum level of sVCAM-1 increased further with a concomitant decrease of the sE-selectin level after clinical recovery from TMA. Because sVCAM-1 is one of the Bone Marrow Transplantation mediators of angiogenesis, 37 this increase might reflect remodeling of damaged vascular endothelium.
Taken together, the data obtained from this study support the notion that activation and injury of endothelium are commonly involved in the pathogenesis of SCT-related complications, such as acute and chronic GVHD, and TMA. Soluble adhesion molecules seem to be valuable markers for predicting and evaluating these SCT-related complications.
